about
Drug repurposing and human parasitic protozoan diseasesGreat efficacy of sulfachloropyrazine-sodium against acute murine toxoplasmosisBayesian models trained with HTS data for predicting β-haematin inhibition and in vitro antimalarial activity.Efficacy, safety and tolerance of imidocarb dipropionate versus atovaquone or buparvaquone plus azithromycin used to treat sick dogs naturally infected with the Babesia microti-like piroplasm.In vitro and in vivo activities of 1-hydroxy-2-alkyl-4(1H)quinolone derivatives against Toxoplasma gondii.Bioluminescence Method for In Vitro Screening of Plasmodium Transmission-Blocking Compounds.1,4-naphthoquinone cations as antiplasmodial agents: hydroxy-, acyloxy-, and alkoxy-substituted analoguesIn vitro anti-Toxoplasma gondii activity of root extract/fractions of Eurycoma longifolia Jack.Efficacy of Malarone(®) in dogs naturally infected with Babesia gibsoni.Parasitic infections in HIV infected individuals: diagnostic & therapeutic challengesAntimalarial pharmacology and therapeutics of atovaquoneOptimization of a multi-well colorimetric assay to determine haem species in Plasmodium falciparum in the presence of anti-malarials.Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.Current advances in detection and treatment of babesiosisAdvances in the epidemiology, diagnosis and treatment of cryptosporidiosis.Defining the timing of action of antimalarial drugs against Plasmodium falciparum.Spirocyclic chromanes exhibit antiplasmodial activities and inhibit all intraerythrocytic life cycle stages.Apoptosis-like cell death pathways in the unicellular parasite Toxoplasma gondii following treatment with apoptosis inducers and chemotherapeutic agents: a proof-of-concept studyCurrent therapies and future possibilities for drug development against liver-stage malaria.Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis.Pneumocystis infection in humans: diagnosis and treatment.Classical and alternative components of the mitochondrial respiratory chain in pathogenic fungi as potential therapeutic targets.New antibacterials for the treatment of toxoplasmosis; a patent review.Mechanism of Action of ME1111, a Novel Antifungal Agent for Topical Treatment of Onychomycosis.Effect of 3-bromopyruvate and atovaquone on infection during in vitro interaction of Toxoplasma gondii and LLC-MK2 cells.The practice of travel medicine: guidelines by the Infectious Diseases Society of America.Menoctone Resistance in Malaria Parasites Is Conferred by M133I Mutations in Cytochrome b That Are Transmissible through Mosquitoes.Cardiac toxoplasmosis after heart transplantation diagnosed by endomyocardial biopsy.Targeting of Helicobacter pylori thymidylate synthase ThyX by non-mitotoxic hydroxy-naphthoquinonesType II NADH dehydrogenase inhibitor 1-hydroxy-2-dodecyl-4(1H)quinolone leads to collapse of mitochondrial inner-membrane potential and ATP depletion in Toxoplasma gondii.Evaluation of naphthoquinones identified the acetylated isolapachol as a potent and selective antiplasmodium agent.Electronic connection between the quinone and cytochrome C redox pools and its role in regulation of mitochondrial electron transport and redox signalingIn vitro antimalarial activity of six Aspidosperma species from the state of Minas Gerais (Brazil).Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis.Solid Lipid Nanoparticles of Atovaquone Based on 2(4) Full-Factorial Design.Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent.Lapachol, a compound targeting pyrimidine metabolism, ameliorates experimental autoimmune arthritis.Biological evaluation of hydroxynaphthoquinones as anti-malarialsCombining Inhibitor Resistance-conferring Mutations in Cytochrome b Creates Conditional Synthetic Lethality in Saccharomyces cerevisiae.Oral atovaquone for the treatment of severe Pneumocystis jirovecii pneumonia in a patient with glucose-6-phosphate dehydrogenase deficiency.
P2860
Q26999453-D82AFAF6-D7A1-49CA-A711-53142F53CD29Q28396159-EECD584C-3661-4474-AD67-DAE6AD21755DQ30883690-D049F55E-6764-43FD-BD36-C151035300ADQ33440113-7BFF2234-219D-4171-A31F-81B81E071990Q33558897-1A5C7FAD-BAD0-45C5-92F1-7CA2A0A1ECA0Q33726679-31F275B5-850F-478F-8AF2-FEABCB3EB3B3Q33752861-4F9AD308-4052-464E-A845-DC5A83645426Q34332413-DFBEE7AF-0740-4A73-A9CE-4BA98443E3A6Q34339537-3F3984BE-3372-40E0-9248-34627DF7C05FQ34635675-E830045B-66CE-4D43-8B91-0053922CC76AQ35131253-82CF2E48-20F6-42B5-BDEA-0E061DCBAA0DQ35794627-CF0CA386-054B-47A5-BC9D-1DAA676D20B9Q35920640-D202504B-18CF-4670-833B-DBE7304580E9Q35969816-69B30F7D-32FE-408C-9915-62A4AA9FE607Q36505502-77C6054C-118B-4CB5-8BC2-E9BDAC4C8591Q36667120-98116322-FDD3-42F7-8A1E-F7784316E3F5Q36724073-0608CB9F-36D1-4977-B42A-0A9A05DF24DAQ36791777-C4C87F49-721A-49AC-82A3-47BD135FA3F4Q36951722-17750ECA-7F2F-4293-B2C3-29E23159AD12Q37625142-A17CE6F3-80AA-4541-8787-632E928813E2Q37762544-441F89AB-79BE-4864-965A-AFD3BDA3EA56Q37832680-DEB68CF6-8A54-4699-A2FD-BFBC7CEFC22FQ37992089-2F8A9631-DBAD-4D8B-85D9-5DBF0C96D0D2Q38367618-8C0D59D4-E3A4-45EE-8CCD-4C90DDC46ED3Q38863836-ECA7E0CF-2B0B-4E64-A670-D6E0A095104BQ39067681-27014A8D-DE3B-4AF4-805B-DC37E4E07607Q39190966-1D7BC1DE-2C04-4BA1-BDCD-27A75EAE9833Q40816149-C946A33B-6A79-49DA-A938-B9A730509792Q41187011-D33A3B3B-8706-45CA-A591-5F5179BD03D8Q41374052-3AF54553-550A-41D1-8BD5-90FB6E8DF11DQ41645035-BC6C86AC-74BE-495D-9C6F-F4E913973621Q41831113-FC5B22EA-0213-4385-B499-EC9C762D677AQ41927545-62CD9CD8-3531-46AE-94B7-333647C5DE49Q41968777-3A1B4793-AE57-4045-8A61-4E63AD37D3A4Q42087508-82FCC62F-EB7A-483B-8291-6D67F29B6434Q42094834-33465058-5ADD-4EE7-A376-E7EB9877F6E1Q42317643-598A8577-4D53-4C6F-BDCD-A13694218E9EQ42710317-BAD3C79C-F57A-42AE-BC29-A22A1D3A82D4Q43158594-1C9E0F58-798F-48D1-B703-DC0F27B578EAQ43250359-CE4237F8-7826-498A-A7C4-67316C0BF0C5
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Antiparasitic agent atovaquone
@ast
Antiparasitic agent atovaquone
@en
Antiparasitic agent atovaquone
@nl
type
label
Antiparasitic agent atovaquone
@ast
Antiparasitic agent atovaquone
@en
Antiparasitic agent atovaquone
@nl
prefLabel
Antiparasitic agent atovaquone
@ast
Antiparasitic agent atovaquone
@en
Antiparasitic agent atovaquone
@nl
P2860
P1476
Antiparasitic agent atovaquone
@en
P2093
Aaron L Baggish
David R Hill
P2860
P304
P356
10.1128/AAC.46.5.1163-1173.2002
P407
P577
2002-05-01T00:00:00Z